U.S. markets closed

  • S&P Futures

    3,916.00
    -12.00 (-0.31%)
     

  • Dow Futures

    31,508.00
    -41.00 (-0.13%)
     

  • Nasdaq Futures

    13,621.00
    -78.75 (-0.57%)
     

  • Russell 2000 Futures

    2,249.30
    -5.70 (-0.25%)
     

  • Crude Oil

    61.63
    +0.49 (+0.80%)
     

  • Gold

    1,782.40
    +9.60 (+0.54%)
     

  • Silver

    27.38
    +0.06 (+0.24%)
     

  • EUR/USD

    1.2041
    -0.0006 (-0.05%)
     

  • 10-Yr Bond

    1.3010
    +0.0020 (+0.15%)
     

  • Vix

    21.50
    +0.04 (+0.19%)
     

  • GBP/USD

    1.3850
    -0.0013 (-0.10%)
     

  • USD/JPY

    105.8460
    -0.0250 (-0.02%)
     

  • BTC-USD

    51,892.42
    +2,411.98 (+4.87%)
     

  • CMC Crypto 200

    1,053.05
    +61.04 (+6.15%)
     

  • FTSE 100

    6,710.90
    -37.96 (-0.56%)
     

  • Nikkei 225

    30,234.58
    -57.61 (-0.19%)
     

TSX Venture Exchange Stock Maintenance Bulletins

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·22 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

VANCOUVER, BC, Feb. 17, 2021 /CNW/ -

TSX VENTURE COMPANIES

AUTOMOTIVE FINCO CORP. ("AFCC")
BULLETIN TYPE: Resume Trading
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

Further to the Exchange bulletin dated February 8, 2021 and the Company's news release dated February 16, 2021, effective at the open on Friday, February 19, 2021, the shares of the Company will resume trading.

_______________________________________

INPUT CAPITAL CORP. ("INP")
BULLETIN TYPE: Declaration of Dividend
BULLETIN DATE: February 17, 2021
TSX Venture Tier 1 Company

The Issuer has declared the following dividend(s):




Dividend per common share:

$0.01

Payable Date:

April 15, 2021

Record Date:

March 31, 2021

Ex-dividend Date:

March 30, 2021

________________________________________

JESMOND CAPITAL LTD. ("JES.P")
BULLETIN TYPE: New Listing-CPC-Shares, Halt
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

This Capital Pool Company's ("CPC") Prospectus dated January 27, 2021 has been filed with and accepted by TSX Venture Exchange and the Alberta and British Columbia Securities Commissions effective January 28, 2021, pursuant to the provisions of the Alberta and British Columbia Securities Acts. The Common Shares of the Company will be listed and immediately halted on TSX Venture Exchange on the effective date stated below.

The Company will complete its initial distribution of securities to the public. The gross proceeds to be received by the Company for the Offering is $350,000 (3,500,000 common shares at $0.10 per share).

Commence Date:

At the opening on Friday, February 19, 2021, the Common Shares
will be listed and IMMEDIATELY HALTED on TSX Venture
Exchange pending receipt and review of acceptable documentation
regarding the Capital Pool Company listing pursuant to Exchange
Policy 2.4.



Corporate Jurisdiction:

Alberta



Capitalization:

Unlimited common shares with no par value of which
9,440,100 common shares are issued and outstanding

Escrowed Shares:

5,940,100 common shares

Transfer Agent:

Alliance Trust Company

Trading Symbol:

JES.P

CUSIP Number:

476870 1 00

Sponsoring Member:

Richardson Wealth Ltd.



Agent's Options:

350,000 non-transferable agent's options exercisable at $0.10
per share up to 24 months from the date of listing.

For further information, please refer to the Company's Prospectus dated January 27, 2021.

Company Contact:

Gordon Chmilar, CFO, Secretary and Director

Company Address:

1600, 421 – 7th Avenue SW
Calgary, Alberta T2P 4K9

Company Phone Number:

(403) 298-1049

Company Email Address:

gordon.chmilar@gowlingwlg.com

________________________________________

PEOPLE CORPORATION ("PEO")
BULLETIN TYPE: Plan of Arrangement, Delist
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange Inc. (the "Exchange") has accepted for filing documentation in connection with the plan of arrangement (the "Arrangement") between People Corporation (the "Company") and 2799825 Ontario Inc. (the "Purchaser"). Pursuant to the Arrangement, the Purchaser, an entity controlled by certain investment funds managed by the Merchant Banking business of Goldman Sachs & Co. LLC, will acquire all of the outstanding common shares of the Company (the "Shares") for C$15.22 in cash per Share, other than certain Shares held by certain senior management shareholders and their affiliates and associates who will receive, in respect of such Shares, consideration consisting of cash and shares of the direct parent of the Purchaser.

The Exchange has been advised that approval of the Arrangement by the Company's shareholders was received at a special meeting of shareholders held on February 11, 2021, and that approval of the Arrangement was received from the Ontario Superior Court of Justice on February 12, 2021. The Arrangement is expected to be completed on February 18, 2021. The full particulars of the Arrangement are set forth in the Company's Management Information Circular dated as of January 13, 2021, which is available on SEDAR.

Delisting:

As a result of and subject to the completion of the Arrangement, the Company will be delisted effective at the close of business on Thursday, February 18, 2021.

________________________________________

STAR ROYALTIES LTD. ("STRR") ("STRR.WT")
BULLETIN TYPE: New Listing-IPO-Shares and Warrants
BULLETIN DATE: February 17, 2021
TSX Venture Tier 1 Company

Star Royalties Ltd.'s (the "Company") initial public offering ("IPO") prospectus dated February 12, 2021, has been filed with and accepted by TSX Venture Exchange, and filed with and receipted on February 12, 2021, by the Ontario Securities Commission (as principal regulator) pursuant to the provisions of the Securities Act (Ontario), and has been filed under Multilateral Instrument 11-102 Passport System in British Columbia, Alberta, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island, and Newfoundland and Labrador. The common shares of the Company (each a "Common Share") will be listed and admitted to trading on TSX Venture Exchange, on the effective date stated below.

Listing Date: At the close of business (5:01 p.m. EST) on Thursday, February 18, 2021.

Commence Date: The Common Shares and warrants will commence trading on TSX Venture Exchange at the opening on February 19, 2021, upon confirmation of closing.

The closing of the IPO is scheduled on February 19, 2021. It is expected that the gross proceeds of the closing will be $24,000,200 for a total of 34,286,000 Units at $0.70 per Unit. A further notice will be issued upon receipt of closing confirmation.

Each Unit shall consist of one Common Share in the capital of the Company and one Common Share purchase warrant (a "Unit Warrant"). Each Unit Warrant shall be exercisable to acquire one additional Common Share at an exercise price of $1.00 until 5:00 p.m. (Toronto time) on the date which is 36 months following the closing of the IPO (the "Closing Date"), pursuant to the terms and conditions of the warrant indenture dated effective February 19, 2021 between the Company and TSX Trust Company, as warrant agent.

New Listing-Shares




Corporate Jurisdiction:

Ontario



Capitalization:

Common Shares with no par value of which
67,304,136 Common Shares are issued and outstanding



Escrowed Shares:

4,901,593 Common Shares



Transfer Agent:

TSX Trust Company

Trading Symbol:

STRR (new)

CUSIP Number:

855169108





Underwriters:

Canaccord Genuity Corp. and Desjardins Securities Inc., as
co-lead underwriters





Over-Allotment Option:

The Company has granted an option to the underwriters' entitling them
to purchase an additional 5,142,900 Units, to raise additional gross
proceeds of up to $27,600,230 up to 30 days following the Closing
Date



Underwriter's Warrants:

Nil issued in connection with the IPO

New Listing-Warrants

Effective at the opening on February 19, 2021, the Common Share purchase warrants of the Company will commence trading on TSX Venture Exchange.

Corporate Jurisdiction:

Ontario

Capitalization:

34,286,000 warrants are issued and outstanding

Transfer Agent:

TSX Trust Company

Trading Symbol:

STRR.WT (NEW)

CUSIP Number:

855169116

These warrants are issued under a warrant indenture dated February 19, 2021 pursuant to the Company's final prospectus dated February 12, 2021. Each warrant entitles the holder to purchase one Common Share of the Company at a price of CDN$1.00 per share expiring on February 19, 2024.

For further information, please refer to the Company's prospectus dated February 12, 2021.

Company Contact: Alexandre Pernin
Company Address: 18 King Street East, Suite 902, Toronto, Ontario, Canada, M5C 1C4
Company Phone Number: (647) 801-3549
Company Email Address: apernin@starroyalties.com

_________________________________

21/02/17 - TSX Venture Exchange Bulletins

TSX VENTURE COMPANIES

ANC CAPITAL VENTURES INC. ("ANCV.P")
BULLETIN TYPE: Halt
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

Effective at 12:38 p.m. PST, February 16, 2021, trading in the shares of the Company was halted at the request of the Company, pending news; this regulatory halt is imposed by Investment Industry Regulatory Organization of Canada, the Market Regulator of the Exchange pursuant to the provisions of Section 10.9(1) of the Universal Market Integrity Rules.

________________________________________

AUMENTO CAPITAL VIII CORP. ("AMU.P")
BULLETIN TYPE: New Listing-CPC-Shares
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

Reference is made to our bulletin dated February 12, 2021, with respect to the listing of the Company's shares.

We have received confirmation that the closing has occurred. Therefore, the common shares of the Company which were listed at the close of business February 16, 2021, commenced trading at the opening of business on Wednesday, February 17, 2021.

The Company has completed its public offering of securities prior to the opening of market on February 17, 2021. The gross proceeds received by the Company for the Offering are $500,000 (1,000,000 common shares at $0.50 per share).

__________________________________________

BAYHORSE SILVER INC. ("BHS")
BULLETIN TYPE: Warrant Term Extension
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has consented to the extension in the expiry date of the following warrants:

Private Placement:




# of Warrants:

7,500,000

Original Expiry Date of Warrants:

December 27, 2019 (as to 1,500,000), January 18, 2020
(as to 2,231,500) and March 2, 20120 (as to 3,768,500),
subsequently extended to March 2, 2021.



New Expiry Date of Warrants:

December 27, 2022 (as to 1,500,000 warrants)
January 18, 2023 (as to 2,231,500 warrants)
March 2, 20120 (as to 3,768,500 warrants)



Exercise Price of Warrants:

$0.30

These warrants were issued pursuant to a private placement of 7,500,000 shares with 7,500,000 share purchase warrants attached, which was accepted for filing by the Exchange effective March 16, 2018, and amended as per bulletin dated December 6, 2019.

________________________________________

BLACKHEATH RESOURCES INC. ("BHR")
BULLETIN TYPE: Halt
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

Effective at 1:33 p.m. PST, February 16, 2021, trading in the shares of the Company was halted at the request of the Company, pending news; this regulatory halt is imposed by Investment Industry Regulatory Organization of Canada, the Market Regulator of the Exchange pursuant to the provisions of Section 10.9(1) of the Universal Market Integrity Rules.

________________________________________

CLOUDMD SOFTWARE & SERVICES INC. ("DOC")
BULLETIN TYPE: Resume Trading
BULLETIN DATE: February 17, 2021
TSX Venture Tier 1 Company

Effective at 8:30 a.m. PST, February 17, 2021, shares of the Company resumed trading, an announcement having been made.

________________________________________

CROWN MINING CORP. ("CWM")
BULLETIN TYPE: Private Placement-Non-Brokered
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing documentation with respect to a Non-Brokered Private Placement announced January 06, 2021:

Number of Shares:

5,000,000 shares



Purchase Price:

$0.10 per share



Warrants:

2,500,000 share purchase warrants to purchase 2,500,000 shares



Warrant Initial Exercise Price:

$0.15



Warrant Term to Expiry:

2 Years



Number of Placees:

10 Placees

Note that in certain circumstances the Exchange may later extend the expiry date of the warrants, if they are less than the maximum permitted term.

Pursuant to Corporate Finance Policy 4.1, Section 1.11(d), the Company has issued a new release dated February 8, 2021, announcing the closing of the private placement and setting out the expiry dates of the hold period(s).

The above information is a summary only. Neither TMX Group Limited nor any of its affiliated companies guarantee the accuracy or completeness of the information contained in this document. Readers should consult the issuer's continuous disclosure record for complete details of the transaction.

________________________________________

E3 METALS CORP. ("ETMC")
BULLETIN TYPE: Halt
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

Effective at 6:56 a.m. PST, February 17, 2021, trading in the shares of the Company was halted at the request of the Company, for a Single Stock Circuit Breaker; this regulatory halt is imposed by Investment Industry Regulatory Organization of Canada, the Market Regulator of the Exchange pursuant to the provisions of Section 10.9(1) of the Universal Market Integrity Rules.

________________________________________

E3 METALS CORP. ("ETMC")
BULLETIN TYPE: Resume Trading
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

Effective at 7:01 a.m. PST, February 17, 2021, shares of the Company resumed trading, an announcement having been made.

________________________________________

ENGINE MEDIA HOLDINGS, INC. ("GAME")
BULLETIN TYPE: Private Placement- Non-Brokered
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing documentation with respect to a Non-Brokered Private Placement announced on December 23, 2020:

Number of Shares:

2,371,747 common shares



Purchase Price:

US$7.50 per common share



Warrants:

1,185,874 share purchase warrants to purchase 1,185,874 common shares



Warrant Exercise Price:

US$15.00 for a period of 36 months



Number of Placees:

252 Placees



Finder's Fee:

An aggregate of $490,640.88, 49,700 units and 114,987 finders' warrants
payable to Richardson Wealth, Mackie Research Capital Corporation, and
Industrial Alliance. Each finder's warrant entitles the holder to acquire one
common share at a price of US$15.00 per share for a period of 36 months.
The units issuable to finders have the same composition as the units issued
pursuant to the offering.

Note that in certain circumstances the Exchange may later extend the expiry date of the warrants, if they are less than the maximum permitted term.

Pursuant to Corporate Finance Policy 4.1, Section 1.11(d), the Company has issued news releases dated January 12, 2021 and January 26, 2021, announcing the closing of the private placement and setting out the expiry dates of the hold period(s).

________________________________________

GMV MINERALS INC. ("GMV")
BULLETIN TYPE: Private Placement-Non-Brokered
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing documentation with respect to a Non-Brokered Private Placement announced Feb 08, 2021:

Number of Shares:

1,458,334 shares

Purchase Price:

$0.24 per share

Warrants:

729,167 share purchase warrants to purchase 729,167 shares

Warrant Initial Exercise Price:

$0.35

Warrant Term to Expiry:

2 Years

Number of Placees:

8 Placees

Insider / Pro Group Participation:




Name

Insider=Y /
Pro-Group=P

# of Shares

DCT Holdings Ltd

Y

208,333

(Alistair MacLennan)



Michele Pillon

Y

10,834

Note that in certain circumstances the Exchange may later extend the expiry date of the warrants, if they are less than the maximum permitted term.

The above information is a summary only. Neither TMX Group Limited nor any of its affiliated companies guarantee the accuracy or completeness of the information contained in this document. Readers should consult the issuer's continuous disclosure record for complete details of the transaction.

________________________________________

GREAT ATLANTIC RESOURCES CORP. ("GR")
BULLETIN TYPE: Private Placement-Non-Brokered
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing documentation with respect to a Non-Brokered Private Placement announced December 3, 2020:

Number of Shares:

384,616 flow-through shares



Purchase Price:

$0.65 per flow-through share



Number of Placees:

1 Placee



Finder's Fee:

Qwest Investment Fund Management Ltd. receives $20,000 cash and 30,769
non-transferable finder's warrants, each exercisable for into one common share
at a price of $0.65 per share for a two-year period.

Pursuant to Corporate Finance Policy 4.1, Section 1.9(e), the Company issued a news release announcing the closing of the private placement and setting out the expiry dates of the hold period on December 3, 2020.

________________________________________

IMETAL RESOURCES INC. ("IMR")
BULLETIN TYPE: Shares for Debt
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing the Company's proposal to issue 195,182 shares to an arm's length creditor at a deemed price of $0.11 and 195,182 share purchase warrants to settle outstanding debt of $21,470.00.

Number of Creditors:

1 Creditors



Warrants:

195,182 share purchase warrants to purchase 195,182 shares



Warrant Exercise Price:

$0.20 for a two-year period

The Company shall issue a news release when the shares are issued and the debt extinguished.

________________________________________

INEO TECH CORP. ("INEO")
BULLETIN TYPE: Resume Trading
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

Effective at 9:45 a.m. PST, February 17, 2021, shares of the Company resumed trading, an announcement having been made.

________________________________________

INNOVOTECH INC. ("IOT")
BULLETIN TYPE: Property-Asset or Share Purchase Agreement
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing documentation a letter agreement ("Agreement") dated October 15, 2020, between the Company and Lonsdale Capital Corporation (the "Vendor"). Pursuant to the terms of the Agreement, the Company will purchase the Vendor's rights, title and interest in and to a convertible debenture ("Debenture"), previously issued on April 13, 2020, with $150,000 in principal amount outstanding and payable by CanBiocin Inc.

The Debenture bears an interest rate of 8% per annum, payable quarterly with the principal amount due and payable monthly in installments of $3,125.00 after the second anniversary date until paid in full. At any time prior to April 15, 2025, the Company will have the option to convert the principal amount and interest outstanding under the Debenture at a conversion price of $1.25 per share of Canbiocin Inc. In return as total consideration, the Company will provide the Vendor with an aggregate of 625,000 common shares at a deemed price of $0.24 per common share.

Insider / Pro Group Participation:






Name

Insider=Y /
ProGroup=P


# of Shares

Lonsdale Capital Corporation



(Alan Savage)

Y

625,000

For further information, please reference the Company's news release dated October 16, 2020.

________________________________________

NGEX MINERALS LTD. ("NGEX")
BULLETIN TYPE: Shares for Bonuses
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing a credit facility effective February 19, 2021 (the "Facility"), between the Company, Zebra Holdings and Investments S.à.r.l. and Lorito Holdings S.à.r.l. (collectively, the "Lenders"), whereby up to US$3,000,000 principal amount will be made available to the Company.

Maturing February 19, 2022, the unsecured Facility bears no interest and is repayable on or before the maturity date.

In consideration, the Company will issue to the Lenders an aggregate of 40,000 common shares on closing and 600 common shares per month for each US$50,000 of principal amount outstanding under the Facility from time to time up to the maturity date.

________________________________________

NORTHERN SHIELD RESOURCES INC. ("NRN")
BULLETIN TYPE: Warrant Term Extension
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has consented to the extension in the expiry date of the following warrants:

Private Placement:




# of Warrants:

1,766,667



Original Expiry Date of Warrants:

March 6, 2021



New Expiry Date of Warrants:

March 6, 2022



Exercise Price of Warrants:

$0.10

These warrants were issued pursuant to a private placement of 4,133,333 units with 2,066,667 share purchase warrants attached, which was accepted for filing by the Exchange effective on March 12, 2019.

________________________________________

NOVA ROYALTY CORP. ("NOVR")
BULLETIN TYPE: Property-Asset or Share Purchase Agreement
BULLETIN DATE: February 17, 2021
TSX Venture Tier 1 Company

TSX Venture Exchange has accepted for filing documentation pertaining to two (2) Purchase Agreements (collectively, the "Agreements") between Nova Royalty Corp. (the "Company") and two (2) arm's length parties (collectively, the "Vendors"), whereby the Company has a acquired a combined, existing 0.18% net smelter return royalty interest (the "NSR Royalties") on the Taca Taca copper-gold-molybdenum project, located in Salta province of Argentina and wholly-owned by First Quantum Minerals Ltd. Together with the Company's previous acquisition of a 0.24% interest in the Taca Taca NSR royalty, it will now hold an aggregate 0.42% interest.

The aggregate purchase price for the NSR Royalties included an upfront cash payment of US$3,000,000 and the issuance of 4,545,454 common shares of the Company on closing.

A finder fee equal to 2% of the transaction value was payable in common shares based on the 5-day VWAP prior to closing, resulting in the issuance of 103,359 shares to Jose Manual Borquez of Santiago, Chile.

For further details, please refer to the Company's news releases dated January 11, 2021 and February 16, 2021.

________________________________________

SPARTAN DELTA CORP. ("SDE")
BULLETIN TYPE: Resume Trading
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

Effective at 7:45 a.m. PST, February 17, 2021, shares of the Company resumed trading, an announcement having been made.

________________________________________

SPECTRA7 MICROSYSTEMS INC. ("SEV")
BULLETIN TYPE: Private Placement-Non-Brokered
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing documentation with respect to a Non-Brokered Private Placement announced December 30, 2020, which relies upon the Notice to Issuers dated April 8, 2020, September 16, 2020 and December 15, 2020:

Number of Shares:

152,009,629 shares



Purchase Price:

$0.03 per share



Warrants

76,004,814 share purchase warrants to purchase 76,004,814 shares



Warrant Exercise Price

$0.05 for a five-year period



Number of Placees:

29 Placees

Insider / Pro Group Participation:


Name

Insider=Y /
ProGroup=P

# of Shares

Ron Pasek

Y

13,388,500




Roger Maggs

Y

1,062,583




John Vettese

Y

2,152,250




Canaccord Genuity Corp.
(Graham Saunders)

P

2,500,000




RF Securities Clearing LP
(Brad Conacher)

P

500,000




RF Securities Clearing LP
(Joel Winkler)

P

600,000




Finder's Fee:

Received an aggregate of $4,500 in cash to Canaccord and $9,204 to RGMP.
310,000 Common Shares and 155,000 Warrants to Lawrence Rhee.

Pursuant to Corporate Finance Policy 4.1, Section 1.9(e), the Company has issued a news release dated February 12, 2021 announcing the closing of the private placement and setting out the expiry dates of the hold periods. Note that in certain circumstances the Exchange may later extend the expiry date of the warrants, if they are less than the maximum permitted term.

________________________________________

SPECTRA7 MICROSYSTEMS INC. ("SEV")
BULLETIN TYPE: Shares for Debt
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing the Company's proposal to issue 9,870,626 shares and 4,935,313 share purchase warrants to settle outstanding debt for $296,118.79, which relies upon the Notice to Issuers dated April 8, 2020, September 16, 2020, and December 15, 2020:

Number of Creditors:

1 Creditor



Warrants:

4,935,313 share purchase warrants to purchase 4,935,313 shares



Warrant Exercise Price:

$0.05 for a five-year period

The Company shall issue a news release when the shares are issued and the debt extinguished.

________________________________________

TNR GOLD CORP. ("TNR")
BULLETIN TYPE: Private Placement-Non-Brokered
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing documentation with respect to a Non-Brokered Private Placement announced Nov 03, 2020:

Number of Shares:

5,000,000 shares



Purchase Price:

$0.05 per share



Warrants:

2,500,000 share purchase warrants to purchase 2,500,000 shares



Warrant Initial Exercise Price:

$0.075



Warrant Term to Expiry:

2 Years



Number of Placees:

11 Placees

Insider / Pro Group Participation:


Name

Insider=Y /
Pro-Group=P

# of Shares

Kirill Klip

Y

2,370,000

Konstantino Klip

Y

180,000

Maurice Brooks

Y

400,000

Gregory Johnson

Y

500,000

Finder's Fee:


Nicholas Winton

$2,625.00 cash

Note that in certain circumstances the Exchange may later extend the expiry date of the warrants, if they are less than the maximum permitted term.

The above information is a summary only. Neither TMX Group Limited nor any of its affiliated companies guarantee the accuracy or completeness of the information contained in this document. Readers should consult the issuer's continuous disclosure record for complete details of the transaction. The closing of this financing was announced in the news releases dated December 29, 2020 and January 15, 2021.

________________________________________

VAXIL BIO LTD. ("VXL")
BULLETIN TYPE: Halt
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

Effective at 6:51 a.m. PST, February 17, 2021, trading in the shares of the Company was halted at the request of the Company, for a Single Stock Circuit Breaker; this regulatory halt is imposed by Investment Industry Regulatory Organization of Canada, the Market Regulator of the Exchange pursuant to the provisions of Section 10.9(1) of the Universal Market Integrity Rules.

________________________________________

VAXIL BIO LTD. ("VXL")
BULLETIN TYPE: Resume Trading
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

Effective at 11:00 a.m. PST, February 17, 2021, shares of the Company resumed trading, an announcement having been made.

________________________________________

VIOR INC. ("VIO")
BULLETIN TYPE: Property-Asset or Share Purchase Agreement
BULLETIN DATE: February 17, 2021
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing the documentation relating to an acquisition agreement (the "Agreement") dated January 28, 2021, between the Company and Sagidor Exploration Inc. (the "Vendor"), in connection with the acquisition of a 100% interest in a group of 24 claims covering 1,398 hectares (the "Property"), located around the city of Belleterre, in the province of Quebec.

The Company will make a cash payment of $20,000 and issue 250,000 common shares to the Vendor in order to acquire a 100% interest in the Property.

The Vendor will retain a 1% net smelter return ("NSR") royalty on any saleable production from the Property. One hundred percent of the NSR royalty (i.e. 1%) may be purchased by the Issuer for $1,000,000

For further information, please refer to the Company's press release dated February 4, 2021.

VIOR INC. (« VIO »)
TYPE DE BULLETIN: Convention d'achat de propriété d'actif ou d'actions
DATE DU BULLETIN: Le 17 février 2021
Société du groupe 2 de TSX Croissance

Bourse de croissance TSX a accepté le dépôt de documents relativement à une convention d'achat (la « convention ») datée du 28 janvier 2021, entre la société et Exploration Sagidor inc. (le « vendeur »), concernant l'acquisition d'un intérêt de 100% dans un groupe de 24 claims couvrant 1 398 hectares (la « propriété ») situé autour de la ville de Belleterre, dans la province du Québec.

La société devra effectuer un paiement en espèces de 20 000 $ et émettre 250 000 actions ordinaires au vendeur afin d'acquérir un intérêt de 100 % dans la propriété.

Le vendeur retiendra une redevance de 1 % au titre du rendement net de fonderie (« NSR ») sur toute production vendable de la propriété. Cent pourcent de la redevance NSR (i.e. 1%) peut être racheté par l'émetteur pour 1 000 000 $.

Pour plus d'information, veuillez-vous référer au communiqué de presse émis par la société le 4 février 2021.

____________________________________

SOURCE TSX Venture Exchange

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/February2021/17/c6717.html

Latest Stories

  • Biden’s $2 Trillion Green Plan Could Send This Stock Soaring

    One massive project changed the face of America in 1935. But now, Biden’s set to continue this plan 85 years later, creating sweeping changes across the nation

  • Warren Buffett's Berkshire Cuts Apple Stake And Buys These Drugmaker, Telecom Stocks Instead

    Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) cut its positions in Apple Inc (NASDAQ: AAPL) and piled on stocks of drug, telecom, and oil companies in the latest quarter, according to filings made with the U.S. Securities and Exchange Commission. What Happened: The Warren Buffett-led company shed its Apple stake by 6% to 887 million shares in the quarter, but at the same time has upped its investments in AbbVie Inc (NYSE: ABBV) by 20%, Bristol-Myers Squibb Company (NYSE: BMY) by 11%, and Merck & Co, Inc (NYSE: MRK) by 28%. The conglomerate increased its exposure to T-Mobile US, Inc (NASDAQ: TMUS) by 1.36% to 5.2 million shares and also added 146.7 million shares of Verizon Communications Inc (NYSE: VZ). See Also: Warren Buffett's Berkshire Bets On These Four Drugmakers Amid Pandemic Berkshire picked up a fresh stake of 48.5 million Chevron Corporation (NYSE: CVX) shares and increased its investment in The Kroger Co (NYSE: KR) by 34%. Other changes include a 59% cut in exposure to Wells Fargo & Co (NYSE: WFC) and a 28% cut in Suncor Energy Inc (NYSE: SU) stake. Why It Matters: Apple is still the largest single investment in Berkshire’s portfolio, as of the latest 13F filing, and the investment is worth about $120 billion. See Also: Warren Buffett Called Bitcoin 'Rat Poison' — Now It's Closing In On Berkshire Hathaway's Valuation Apple shares closed nearly 1.6% lower at $133.19 on Tuesday and fell another 0.41% in the after-hours session. In the after-hours trading on Tuesday — AbbVie shares were up 0.42% at $104.64. Bristol-Myers shares rose 0.34% to $59.60. T-Mobile shares rose 0.86% to $123.05. Verizon shares shot up 3.05% to $55.80 in the after-hours trading, while Chevron shares rose 2.54% to $95.50. Wells Fargo shares were down 0.11% in the after-hours. Kroger and Suncor shares remained largely unchanged. Price Action: Berkshire Hathaway Class A shares closed 1.23% higher at $369,333. The company’s class B shares closed 1.15% higher at $245.28 and fell 0.11% in the after-hours session. Photo by Fortune Live Media on Flickr See more from BenzingaClick here for options trades from BenzingaTikTok In Negotiations To Go Public On NYSE: Chinese MediaWhy Apple Getting Increasingly Serious About Making Cars? 'Transportation' Dwarfs 'Smartphone' Market, Says Munster© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Stocks To Watch: Square Among 7 Stocks Expecting Up To 128% Growth In 2021

    What are the fastest-growing stocks to watch in 2021? Here's a list featuring DocuSign, Square, Daqo and four other stocks expecting up to 128% growth.

  • Cathie Wood Talks Tesla, Bitcoin, SPACs And More On CNBC: Here Are The Highlights

    Famed investor and ETF manager Cathie Wood joined Scott Wapner and Bob Pisani on the “Halftime Report” on CNBC Wednesday to share opinions on some holdings across her funds. Wood On Tesla: Wood has been a notable bull on Tesla Inc (NASDAQ: TSLA) and it remains the largest holding in the signature Ark Innovation ETF (NYSE: ARKK). “Our confidence in Tesla has grown,” Wood said. The fund manager said no one is modeling the ride-share potential for Tesla when forecasting revenue and price targets. Rideshare could be more profitable for Tesla than electric vehicles. Related Link: 7 Stocks That Fit Cathie Wood’s Big Ideas 2021, Could Be Added To Ark ETFs Wood On Bitcoin: Wood has been bullish on Bitcoin recently hitting on the rise in valuation that could be seen if every S&P 500 company allocated 1% of cash to the cryptocurrency. “We have individuals now who really understand,” Wood said on Gary Gensler, the new U.S. SEC Chair. Gensler taught a class on blockchain and Bitcoin at MIT and understand the technology and valuation, Wood added. The Grayscale Bitcoin Trust (OTC: GBTC) is a popular option for investors in the U.S. to get exposure to Bitcoin as no ETFs are available currently. Wood said the probability of a Bitcoin ETF goes up with new administration understanding cryptocurrency. The fund manager praises companies like Tesla and Square Inc (NYSE: SQ) who are “on the right side of change” by adding Bitcoin and diversifying their cash holdings. Wood On Telemedicine: One of the largest holdings in the Ark ETFs is Teladoc Health (NYSE: TDOC). The telemedicine company is held in the Ark Innovation ETF, Ark Genomic Internet ETF (BATS: ARKG) and Ark Next Generation Internet ETF (NYSE: ARKW). “We had a great opportunity to buy into Teladoc when stay-at-home stocks flattened out,” Wood said. Despite the stock being up 40% in 2021, Wood remains bullish and thinks the company was hurt by public sentiment of the acquisition of Livongo. “This is a beautiful acquisition for Teladoc,"Wood said, adding that the two companies will create a powerhouse of data together. Wood on SPACs: The Ark fund manager has added several SPACs to the portfolio recently, including some that have completed mergers and others like Experience Investment (NASDAQ: EXPC) that are in the merger process. Wood named DraftKings Inc (NASDAQ: DKNG), Skillz (NYSE: SKLZ) and Butterfly Network Inc (NYSE: BFLY) as former SPACs that the Ark funds own. “We are investing in them,” Wood said of SPACs. “We’re being very careful.” Wood said the fund is selective and doesn’t like the incentive structure of some SPACs. The fund manager noted SPACs remain a way for the public markets to invest in some growth sooner than the traditional IPO route. Space ETF: Wood is launching a space ETF under the Ark umbrella of funds soon. Due to a quiet period with the SEC, Wood couldn’t discuss specific space stocks, but was bullish on the overall industry. She called space exploration the right side of change. “We see SpaceX, Blue Origin pushing the envelope,” Wood said of the private companies. She highlighted the work that Elon Musk, Jeff Bezos and Richard Branson have done in the space industry. The costs of launching rockets are coming down dramatically, which could lead to strong growth in the sector, according to Wood. See more from BenzingaClick here for options trades from BenzingaQuantumScape Could Have Breakthrough EV Battery Technology: WedbushOrigin Materials Lands SPAC Deal: What Investors Should Know About Pepsi-, Danone-, Nestle-Backed Company© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Palantir Stock Falls As 2021 Revenue Outlook Disappoints, IPO Lock-Up To Expire

    Palantir stock fell as full-year 2021 revenue guidance came in slightly below expectations. Palantir stock also faces a test on Thursday when its IPO lock-up period expires.

  • Warren Buffett is right to bet big on 5G: former Cisco CEO

    Former Cisco CEO John Chambers weighs in on Warren Buffett's big bets on 5G.

  • The Bottom Is in for These 2 Stocks? Analysts Say ‘Buy’

    Today, we’re looking at two small-cap biotech firms whose stocks have struck a rut. Each company has hit a recent clinical setback that sent the share price falling, erasing previous gains and sending it back down to low levels. Setbacks of this sort are not uncommon in the biotech industry, and in fact highlight the risk and speculative nature of the industry. So what should investors do, when a stock collapses? Is this a matter of poor fundamentals? And has the stock’s price found its low point yet? That’s where the Wall Street pros come in. Noting that each is set to take back off on an upward trajectory, some 5-star analysts see an attractive entry point for both. Using TipRanks’ database, we found out that these two tickers have earned Moderate or Strong Buy consensus ratings from the analyst community, and boast strong upside potential. Cortexyme, Inc. (CRTX) The first beaten-down name we're looking at is Cortexyme, a clinical-stage biopharma company focused on degenerative diseases, especially Alzheimer’s. The company's lead candidate is COR388, also called atuzaginstat. Atuzaginstat is currently under investigation in the GAIN trial, a study of its efficacy against Alzheimer’s disease. The trial is fully enrolled, with 643 patients, and the company was moving toward an open label enrollment (OLE) section of the Phase 2/3 study. During a routine regulatory update, Cortexyme announced that the OLE phase would be halted, although the primary GAIN study will continue, with results due to be released in Q4 2021. The announcement of the partial halt triggered a 35% drop in share price. The partial hold was prompted by adverse events on the liver during the atuzaginstat trial. The hepatic symptoms were reversible and showed no long-term lasting effects. The FDA reviewed these records, and in collaboration with Cortexyme the decision was made to hold the OLE while continuing with GAIN. This decision allows the main thrust of the program to continue, while working out a new protocol for the OLE. The purpose of the OLE is to test long-term efficacy and tolerability of the drug. In a review of Cortexyme after the announcement, HC Wainwright’s 5-star analyst Andrew Fein noted, “Cortexyme's announcement of a partial clinical hold on the OLE study of atuzaginstat is disappointing, but the reversible nature of the liver toxicity might provide some ray of hope for Cortexyme. We believe that the pivotal trial's continuation suggests that the drug-induced liver injury might not be severe enough to halt the program.” Turning to the near-term, Fein adds, “Continuation of the GAIN trial is encouraging despite the partial hold on OLE. It suggests that FDA plans to wait for the additional data from the pivotal trial before coming to any conclusion. Management shared that nearly one-third of the GAIN patients have completed the study and way past the 12-week time point, suggesting that they are out of risk.” To this end, Fein rates CRTX a Buy, and his $76 price target indicates confidence in a 147% growth potential. (To watch Fein’s track record, click here) Overall, Cortexyme has a Moderate Buy rating from the analyst consensus, with 6 recent reviews breaking down 4 to 1 to 1, Buy-Hold-Sell. The stock’s $83.60 average price target suggests that Wall Street sees a high potential here, on the order of ~170% upside from the trading price of $30.74. (See CRTX stock analysis on TipRanks) Immunovant (IMVT) Next up is Immunovant, a clinical stage biopharmaceutical research firm, focused on developing treatments for patients with autoimmune disorders, a class of diseases in which the immune system attacks the patient’s own body. The firm’s lead drug candidate, IMVT-1401, is undergoing trials as a treatment for thyroid eye disease, myasthenia gravis, and warm autoimmune hemolytic anemia. The drug described as “a novel, fully human anti-FcRn monoclonal antibody,” delivered by subcutaneous injection. On February 2, Immunovant’s stock plunged 42%, and it has been falling ever since. The precipitating factor was an announcement by the company that IMVT-1401 has had its Phase 2b clinical trial, for thyroid eye disease, halted temporarily, due to patients experiencing dangerous rises in their LDL levels. LDLs are the potentially harmful form of cholesterol, which have been connected to cardiovascular disease. Despite the clinical setback, Stiffel’s 5-star analyst Derek Archila reiterated a Buy rating on IMVT shares, along with a $28 price target. This figure suggests a 52% upside potential from current levels. (To watch Archila’s track record, click here) “Interestingly, increases have only been seen in TED patients, and our review of the literature suggests a few things: (1) it's likely this is TED specific given the biology- see below for details, but we don't think similar LDL increases will be seen in other indications outside TED; and (2) other anti-thyroid therapies used in Graves/TED also see similar increases in LDL, which end up being transient. We think IMVT-1401, in away, is replicating this mechanism," the analyst noted. Archila summed up, "While we will need to see additional data from the company to confirm... we don't think this program is dead.” Overall, the Strong Buy analyst consensus view on IMVT would suggest that Wall Street generally agrees with Archila’s assessment. This rating is derived from 8 recent reviews, which include 7 Buys and only a single Hold. The average price target here stands at $40.38, implying ~121% upside for the next 12 months. (See IMVT stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Warren Buffett's favorite indicator is at a dangerous level, but he just bought these stocks anyway

    Warren Buffett goes on the hunt for stocks in the fourth quarter, according to a new filing.

  • Should AT&T Or Verizon Try To Acquire Nokia In 2021?

    Every week, Benzinga conducts a survey to collect sentiment on what traders are most excited about, interested in or thinking about as they manage and build their personal portfolios. This week we posed the following question to over 1,000 traders and investors as to if 5G wireless giants AT&T Inc. (NYSE: T) or Verizon Communications Inc. (NYSE: VZ) should acquire Nokia (NYSE: NOK) in 2021: AT&T should buy Nokia Verizon should buy Nokia Neither should buy Nokia Given AT&T and Verizon are the nation’s largest wireless carriers, it’s expected they will be the most competitive companies angling for the largest market share of 5G cellular technology in the coming years. Verizon is the largest U.S. wireless carrier, serving about 89 million postpaid and 4 million prepaid phone customers. AT&T is the second-largest U.S. wireless carrier, with 63 million postpaid and 16 million prepaid phone customers. Verizon + Nokia: As far as active business relationships are concerned, in October Verizon teamed up with Nokia to offer private 5G capabilities to enterprises across Europe and Asia-Pacific territories. Private 5G will enable organizations to deliver mission-critical and real-time capabilities and Verizon's continued investment in 5G and network-as-a-service strategy, the companies said. See Also: How To Buy Verizon Stock AT&T + Nokia: As is the case with Verizon, it’s no secret AT&T and Nokia have an active partnership in place to leverage their 5G technologies. The agreement between AT&T and Nokia highlights how AT&T’s enterprise customers can connect and manage a multitude of Internet of Things (IoT) devices on their networks, leveraging Nokia WING’s capabilities, including increased performance and flexibility, and lower latency. The current AT&T-Nokia partnership also underscores how, as IoT networks transition to 5G and with Nokia WING also supporting 5G network slicing, AT&T will be able to partition its 5G network into multiple networks that can deliver specific capabilities to its IoT customers and support various use cases. Survey Says: While the 5G partnership caught the eye of our respondents, only 28% felt Verizon should move forward with completing an M&A with Nokia by the end of the year. About 30% of respondents believe an AT&T-Nokia makes sense in 2021. Meanwhile, 42% of respondents told us both AT&T and Verizon ought not attempt an M&A deal in 2021. Many respondents simply believe Nokia has the possibility to revamp itself, or that Nokia simply carries too much debt for AT&T and Verizon to bother taking on. Nokia's long-term debt stands at $5.1 billion at the time of publication. See more from BenzingaClick here for options trades from BenzingaHere's Why MicroVision, Verizon And Slack Are MovingWe Asked 1,000 Readers If Tesla Or Nio Makes The Cooler-Looking EV© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • We were ‘dangerously close’ to collapse of ‘entire system,’ says Interactive Brokers founder ahead of GameStop hearing

    Thomas Peterffy, founder and chairman of Interactive Brokers Group Inc., on Wednesday explained the dire situation in which the market stood in late January as individual investors on social-media platforms were banding together to send a handful of heavily shorted stocks dramatically higher.

  • Warren Buffett Dumped GOLD Stock Ahead Of Gold-Price Death Cross

    Massive new fiscal spending under Democrats supports the gold bull case long term, but faster Fed tightening could weigh on gold for a while.

  • ‘Roaring Kitty’ Sued for Securities Fraud Over GameStop Rise

    (Bloomberg) -- Keith Gill, one of the most influential voices that pushed GameStop on the WallStreetBets Reddit forum, was hit with a lawsuit that accused him of misrepresenting himself as an amateur investor and profiting by artificially inflating the price of the stock.The proposed class action against Gill, who adopted the YouTube nickname “Roaring Kitty,” was filed Tuesday in federal court in Massachusetts. The suit said Gill was actually a licensed securities professional who manipulated the market to profit himself. Gill touted GameStop shares through an extensive social media presence on Youtube, Twitter and Reddit, where he used a more profane alias.“Gill’s deceitful and manipulative conduct not only violated numerous industry regulations and rules, but also various securities laws by undermining the integrity of the market for GameStop shares,” the suit said. “He caused enormous losses not only to those who bought option contracts, but also to those who fell for Gill’s act and bought GameStop stock during the market frenzy at greatly inflated prices.”The suit was filed by the securities class action firm Hagens Berman Sobol Shapiro on behalf of Christian Iovin of Washington state and similarly situated individuals. Iovin sold $200,000 worth of call options on GameStop shares when the stock was below $100. The stock quickly eclipsed $400 a share, forcing him to buy the calls back at elevated prices.Gill became one of the public faces of the GameStop rally that has been a Wall Street obsession this year. The stock’s stratospheric rise appeared to pit scrappy individual investors against sophisticated hedge funds who were heavily shorting the troubled mall retailer. Some funds lost billions of dollars covering their positions as GameStop shares surged more than 1,700% during one stretch in January.Congressional TestimonyThe GameStop rally has also attracted the attention of politicians, and Gill is scheduled to testify Thursday before the House Financial Services Committee, along with executives from Robinhood Markets, Citadel LLC, Melvin Capital Management and Reddit.In prepared testimony for his Congressional appearance, provided in advance by his lawyer in response to questions about the lawsuit, Gill said his previous work in the financial industry never included trading securities or advising clients. He also denied trying to artificially pump up GameStop shares and said he truly believed in the company’s future potential.“I did not solicit anyone to buy or sell the stock for my own profit,” Gill plans to testify. “I did not belong to any groups trying to create movements in the stock price. I never had a financial relationship with any hedge fund. I had no information about GameStop except what was public. I did not know any people inside the company, and I never spoke to any insider.”‘Millionaires’ in DecemberIt’s unclear how much money Gill made from his GameStop shares, though he said in his testimony that he and his family were “millionaires” when the stock reached $20 in December, far below the heights it would reach a month later. Those gains have largely evaporated in recent weeks, with the stock trading around $47 on Wednesday afternoon.The lawsuit claims Gill, who has been written about extensively by Bloomberg, The New York Times, The Wall Street Journal and others, was far from being an amateur stock picker. Rather, he is a Chartered Financial Analyst who holds multiple broker licenses and was previously employed by Massachusetts Mutual Life Insurance Co. The lawsuit also named Mass Mutual and a brokerage subsidiary of the company as defendants, saying they had an obligation to supervise Gill’s activities in the market.A spokeswoman for Mass Mutual said the company was reviewing the matter and had no comment.“In order to motivate amateur traders, Gill fashioned himself as a kind of Robin Hood and characterized securities professionals as villians,” the lawsuit said. “Gill, however, is no amateur. For many years, he actively worked as a professional in the investment and financial industries.”The case is Iovin v. Gill, 21-cv-10264, U.S. District Court District, District of Massachusetts (Springfield).(Updates with Gill’s planned testimony to Congress)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • When to expect your next stimulus check? These dates are key to the timing

    Congress is burning rubber to get a bill to President Biden in a race against time.

  • Elon Musk Loses No. 1 Status As Tesla Stock Falls, But SpaceX Value Jumps

    Jeff Bezos is again the richest person in the world, reclaiming his title from Elon Musk, who has seen his wealth lag with the recent drop in Tesla stock.

  • What Rate of Return Should I Expect on My 401(k)?

    There's no one number. Pinpoint what you’ll need in retirement and your time frame until that day, and derive what to expect from your 401(k) from that.

  • Tilray Beats Some Earnings Views, Achieves This Rare Feat Among Marijuana Stocks

    Tilray beat some Q4 expectations, and became the rare weed company to deliver on its profitability goals.

  • 3 Top Biotech Stocks With Major Catalysts Approaching

    Investors are always searching out the stock market’s best opportunities. One of the go-to places for outsized returns, is the biotech sector. These companies, like investors, are also on a quest; to find medical solutions where needed. When one strikes medical gold, the rewards can be phenomenal for early investors who were quick to recognize the potential. However, where the space offers handsome reward, it is fraught with risk. Should a company fail to deliver the requirements to bring a treatment to market, the implications can be brutal for the stock, and therefore, to investors’ pockets. After the completion of clinical tests, the final hurdle in getting a drug approved is a date with the regulators. PDUFA (Prescription Drug User Fee Act) dates – the deadline of the FDA’s review of new drugs - determine whether a treatment is fit for purpose or not and a yay or nay can act as a major catalyst to send shares either soaring or crashing. With this in mind, we opened the TipRanks database to get the lowdown on three biotech stocks awaiting upcoming PDUFA dates. All are currently Buy-rated, with Street analysts predicting strong gains in the year ahead. Cormedix (CRMD) We'll start off with Cormedix, a biopharma company specializing in the field of infectious and inflammatory diseases, whose PDUFA date is fast-approaching. Cormedix’ sole focus right now is Defencath, a synthetic broad-spectrum antimicrobial and antifungal drug, and on February 28, the FDA will decide whether it cuts the mustard. The company has been developing the treatment to thwart catheter-related bloodstream infections (“CRBSIs”) in patients with end-stage renal disease receiving hemodialysis via a central venous catheter. Defencath is already on the market in Europe and other regions going by the brand name of Neutrolin. B. Riley analyst Andrew D’Silva thinks the FDA’s recent actions bode well for the drug's chances of approval. "CRMD was granted priority review for the candidate, which reduced the FDA's review time of the submission from ~10 months to ~6 months, and the FDA subsequently determined an AdCom meeting was not needed. As a result, we are increasing the probability of success related to an FDA approval from 70% to 85%, which is in line with typical approval rates seen for candidates once an NDA/BLA have been submitted," D’Silva commented. Taking onto account the candidate’s Phase 3 study results, in which the treatment showed a statistically meaningful drop of 71% in CRBSI in patients undergoing hemodialysis compared to heparin, D’Silva thinks Defencath could save the healthcare system around $1 billion a year. This is without even taking into account the “benefits related to reduced antibiotic use, improved quality of life, reduced mortality, or a willingness-to-pay (WTP) per quality-adjusted life year (QALY) gained.” D’Silva’s calculations lead him to believe Cormedix’ TAM (total addressable market) for hemodialysis is in the region of $1.7 billion. In line with his optimistic approach, D’Silva rates CRMD an Outperform (i.e. Buy) along with a $25 price target. Should his thesis play out, a potential gain of 75% could be in the cards. (To watch D’Silva’s track record, click here) Overall, CRMD shares get a unanimous thumbs up, with 4 Buys backing the stock’s Strong Buy consensus rating. Shares sell for $14.30, and the average price target of $22 suggests an upside potential of ~54% from that level. (See CRMD stock analysis on TipRanks) Kiniksa Pharmaceuticals (KNSA) Next up, we have Kiniksa Pharmaceuticals, and unlike Cormedix, the company has a varied pipeline of drugs in different stage of progress - all focusing on weakening diseases with significant unmet medical need. The upcoming catalyst for Kiniksa is the March 21 PDUFA date for rilonacept, for the treatment of recurrent pericarditis (RP), an agonizing and debilitating autoinflammatory cardiovascular disease. The FDA has granted both orphan drug and breakthrough therapy status for the treatment which showed positive topline results in the Phase 3 study. With roughly 40,000 patients with RP in the U.S. either looking for or undergoing medical treatment, Kiniksa’s focus is on bringing to market a treatment that not only addresses the symptoms of a pericarditis recurrence but also lowers the probability of future recurrences. Among the fans is Wedbush analyst David Nierengarten, who believes the company has the right approach. “We believe the commercial messaging is sound and straightforward: in addition to the impressive top-line efficacy, key secondary endpoints of patient-reported quality-of-life and tapering of background medication support its use,” the 5-star analyst opined. The analyst added, “In all, we see KNSA’s rational commercialization strategy for rilo as encouraging and expect the program to be well received by cardiologists who treat disproportionate numbers of recurrent pericarditis patients and by patients given the rapid onset of convincing benefit.” Based on all of the above, Nierengarten rates KNSA an Outperform (i.e. Buy) along with a $35 price target. This target puts the upside potential at 55%. (To watch Nierengarten’s track record, click here) Other analysts share a similar enthusiasm with Nierengarten when it comes to KNSA. As 3 Buy ratings were assigned in the last three months compared to no Holds or Sells, the consensus is unanimous: the stock is a ‘Strong Buy’. Meanwhile, its $31.67 average price target puts the potential twelve-month gain at ~40%. (See KNSA stock analysis on TipRanks) Aveo Pharmaceuticals (AVEO) Hoping to provide better outcomes for patients, AVEO Pharmaceuticals advances targeted medicines for oncology and other unmet medical needs. The company has various drugs in development, but the focus right now is on the FDA’s upcoming decision for Tivozanib, the company’s drug for the third and fourth-line treatment of advanced renal cell carcinoma (RCC). The drug is already approved to treat adult patients with advanced renal cell carcinoma (RCC) in other regions, specifically in the European Union, Norway, New Zealand and Iceland. The PDUFA date is slated for March 31 and following the positive data from the late-stage study, Baird analyst Michael Ulz believes a successful outcome is in the cards. “tivozanib was shown to significantly increase quality-adjusted time without symptoms or toxicity (Q-TWiST) compared to sorafenib (15.04 vs. 12.78 months; p=0.0493), further highlighting a differentiated tolerability profile based on a quality-of-life measure for tivozanib, despite similar overall survival (OS) outcomes... We continue to see potential for approval based on the TIVO-3 study and expect investor focus to remain on the upcoming PDUFA date (March 31), which we view as the next key catalyst," Ulz opined. To this end, Ulz rates AVEO a Buy along with a $17 price target. The implication for investors? Upside of 106%. (To watch Ulz's track record, click here) It has been relatively quiet when it comes to other analyst activity. In the last three months, only 2 analysts have issued ratings. However, as they were both Buys, the word on the Street is that AVEO is a Moderate Buy. Based on the $13.50 average price target, shares could climb ~64% higher in the next twelve months. (See AVEO stock analysis on TipRanks) To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Apple stock breaks below post-COVID uptrend line after largest shareholders disclose share sales

    Shares of Apple Inc. sank toward a one-month low Wednesday, and broke below two key chart levels in the process, after the technology behemoth's two largest shareholders disclosed that they trimmed their stakes.

  • Lithium producer Albemarle expects recovery in sales as results top estimates

    After the coronavirus dented growth prospects last year, Albemarle and its peers like SQM are now expecting to cash in on surging demand for the battery metal lithium, critical to electric vehicles that have become massively popular amid climate change concerns. Albemarle has earlier said it looks to double production at its lithium facility in Silver Peak, Nevada, part of a plan to boost supply for the burgeoning electric vehicle market, while Chilean miner SQM has said its current plans to boost its production of lithium carbonate and lithium hydroxide by the second half of 2021 remained on track. However, Albemarle warned that it expects pricing to be down slightly, and forecast adjusted profit in the range of $3.25 to $3.65 per share for 2021.

  • Dow Jones Futures: Federal Reserve, Tesla 'Confidence' Stem Growth Sell-Off; Twilio, Tilray Lead Earnings Movers

    Fed comments and "confidence" in Tesla stock helped growth stocks pare losses, but investors should pay attention. Twilio and Tilray led earnings movers late.